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eduction in C-Reactive Protein Through
ardiac Rehabilitation and Exercise Training
ichard V. Milani, MD, FACC, Carl J. Lavie, MD, FACC, Mandeep R. Mehra, MD, FACC
ew Orleans, Louisiana
OBJECTIVES This study was designed to assess the effects of three-month formal phase II cardiac
rehabilitation and exercise training programs on high-sensitivity C-reactive protein (HSCRP)
levels in patients with coronary heart disease (CHD).
BACKGROUND High-sensitivity C-reactive protein is associated with abdominal adiposity and other CHD
risk factors and is a potent independent predictor of CHD events. Although weight reduction
and statin therapy reduce HSCRP levels, the independent effects of cardiac rehabilitation
programs on HSCRP are not well established.
METHODS We analyzed plasma levels of HSCRP in 277 patients with CHD (235 consecutive patients
before and after formal phase II cardiac rehabilitation and exercise training programs and 42
“control” patients who did not attend cardiac rehabilitation). Additionally, we determined the
effects of cardiac rehabilitation on HSCRP independent of statin therapy and weight loss.
RESULTS Rehabilitation patients improved significantly in body fat, obesity indices, exercise capacity,
and other cardiac risk factors. Mean (5.9  7.7 to 3.8  5.8 mg/l; 36%; p  0.0001) and
median levels of HSCRP (41%; p  0.002) decreased significantly in the rehabilitation
group but not in the control population. Similar significant reductions in HSCRP occurred
in the rehabilitation patients regardless of whether they received statin therapy or lost weight.
CONCLUSIONS Therapeutic lifestyle changes effected through a three-month cardiac rehabilitation program
significantly improved numerous cardiac risk factors. Through this holistic approach to secondary
prevention, we observed significant reductions in HSCRP levels. These findings identify another
clinical modality of reducing HSCRP beyond use of statin drugs and suggest an additional benefit
of formal phase II cardiac rehabilitation and exercise training programs. (J Am Coll Cardiol
2004;43:1056–61) © 2004 by the American College of Cardiology Foundationtherothrombosis is recognized as a dynamic chronic inflam- proven modality for reducing the overall burden of cardiovas-
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tatory process of the vessel wall in which phases of inflam-
atory and thrombotic activity underlie the clinical presenta-
ion of acute coronary syndromes (ACS) (1,2). Research has
uggested that inflammatory markers, such as high-sensitivity
-reactive protein (HSCRP), provide an alternative method
or global assessment of cardiovascular risk (3–5). Several
rospective studies have shown that plasma levels of HSCRP
re a strong independent predictor of risk of future vascular
vents among individuals with and without known cardiovas-
ular disease, including those patients who have been recently
ischarged from an ACS (5–12).
Elevated levels of HSCRP have been positively correlated
ith most cardiovascular risk factors, and have a strong
ssociation with adiposity and to a lesser extent physical
nactivity (13–17). We have recently demonstrated the
trong association between metabolic syndrome and ele-
ated levels of HSCRP in our coronary heart disease
CHD) population (18). At the present time, proven
herapies to reduce high-risk HSCRP levels include weight
eduction (19) and, particularly, statin therapy (11,20–22).
Although cardiac rehabilitation and exercise training is a
From the Cardiovascular Health Center, Department of Cardiology, Ochsner
linic Foundation, New Orleans, Louisiana. Presented in part at the 74th Annual
cientific Sessions of the American Heart Association, Anaheim, California, Novem-
er 11 to 14, 2001.
Manuscript received July 15, 2003; revised manuscript received September 26,e003, accepted October 6, 2003.ular risk, and can be effective in reducing body fat and
nhancing exercise capacity in patients following major cardiac
vents (23–26), the effects of this therapy on HSCRP are not
ell established. However, we have recently reported marked
eductions in levels of HSCRP in our patients with metabolic
yndrome following cardiac rehabilitation (18).
In the present study, we sought to determine the effects of
vigorous nonpharmacologic program of formal phase II
ardiac rehabilitation and exercise training on levels of
SCRP in patients following major cardiac events and to
etermine if this therapy reduces HSCRP independent of
tatin therapy and weight loss.
ETHODS
e reviewed the case records of 235 consecutive patients with
HD (72% percutaneous intervention [PCI], 19% bypass
urgery, and 28% myocardial infarction) completing a three-
onth formal program of cardiac rehabilitation and exercise
raining to ascertain relevant anthropometric, lipid, and clinical
ata. This study was approved by the Institutional Review
oard at Ochsner Clinic Foundation. Detailed program com-
onents have been reviewed elsewhere (23–26), but in brief,
atients received both individual and group counseling from a
egistered dietitian in dietary management as recommended by
he Adult Treatment Panel III guidelines, as well as special
mphasis on the Mediterranean diet (27,28). In overweight
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rder to promote weight loss. Patients received formalized
xercise instruction and met three times per week for group
xercise classes, and were encouraged to exercise on their own
1 to 3 times per week) in between sessions. Although
ompliance with formal rehabilitation and exercise sessions was
ssessed, we did not record compliance with home exercise
requency or duration. Patients’ exercise recommendations
ere tailored towards the anaerobic threshold achieved during
ntry testing. Specific weight management guidance was given
o those overweight and obese subjects. Educational classes
ere given with regards to all aspects of CHD risk including
ypertension, smoking cessation, and diabetes management.
A group of 42 subjects who entered rehabilitation during
he same time period, but dropped out before beginning
ctive participation in the program, agreed to serve as a
ontrol group for the purpose of monitoring HSCRP,
ipids, and body mass index (BMI) over time; these patients,
owever, did not have cardiopulmonary exercise tests. All
ubjects underwent initial evaluation including HSCRP
ssessment two to six weeks following hospital discharge,
nd repeat measurements of these parameters were per-
ormed between three and six months following initial
esting. The principal reasons for not participating in the
rogram were financial (55%) and traveling distance to the
ehabilitation facility (33%). The diagnoses of control sub-
ects included 79% following PCI, 21% after coronary
ypass, and 24% with myocardial infarction.
In all rehabilitation patients, fasting lipids, glucose,
SCRP, percent body fat, abdominal girth, and resting
lood pressure were obtained on the same day prospectively
pon entry and completion of the formal rehabilitation
rogram. The majority of subjects entered the program
etween three and five weeks following hospital discharge.
igh-sensitivity assays for CRP were performed according
o methods described by the manufacturer (Dade Behring
nc., Deerfield, Illinois) (29). The percentage of body fat
as determined by the skinfold technique using the average
f three skinfolds (thigh, chest, and abdomen in men; thigh,
riceps, and suprailium in women) (30,31). All measure-
ents were made in the early morning before exercise.
Patients and control subjects who were taking either
ipid-lowering medication (65% of rehabilitation patients,
0% of control subjects), including statins, or hormone
eplacement therapy remained on constant doses for a
eriod of at least six weeks before the initial assessment and
Abbreviations and Acronyms
ACS  acute coronary syndromes
BMI  body mass index
CHD  coronary heart disease
HSCRP  high-sensitivity C-reactive protein
PCI  percutaneous coronary intervention
VO2  oxygen consumptionhroughout the evaluation period.Means or proportions for baseline risk factors were
omputed for all subjects, and the significance of any
ifferences in means tested with the Student t test; differ-
nces in proportions were tested with the chi-square statis-
ic. Because the distributions of CRP are rightward skewed,
edian concentrations were computed for this parameter
nd the significance of any differences assessed using the
ilcoxon rank-sum test. Statistical analysis using paired
nd unpaired t test was performed using Statview 5.0.1
SAS Institute, Cary, North Carolina). A value of p  0.05
as considered statistically significant, and variability is
eported using standard deviation.
ESULTS
aseline data on the 235 patients enrolled in the rehabilitation
rogram are detailed in Table 1. In our rehabilitation cohort,
7 (29%) patients were women (33% on hormone replacement
herapy), and the mean age of our cohort was 66  11 years.
aseline assessment (including HSCRP) was obtained 29 
0 days in rehabilitation patients and 32  12 days in control
atients following the cardiac event (pNS between groups).
he mean BMI of the cohort was 27.9  4.9 kg/m2, and the
ean percentage of body fat was 28.7% 7.8%. Of note, 38%
f subjects upon entry were classified as overweight (BMI25
g/m2 and30 kg/m2), and an additional 31% were classified
s obese (BMI 30 kg/m2). The median concentration of
SCRP at entry was 3.4 mg/l (range 0.2 to 48.2 mg/l); mean
oncentration was 5.9  7.7 mg/l at baseline. 143 patients
61%) were on statin therapy upon entry and during the
hree-month rehabilitation program. An additional 10 patients
4%) were on either fibrate or niacin therapy. At entry,
SCRP was weakly, but significantly, correlated to BMI (r
.114; p  0.05), but did not correlate with other baseline
actors, including peak exercise capacity.
able 1. Baseline Differences Between Rehabilitation and
ontrol Subjects
Rehabilitation
(n  235)
Control
(n  42) p Value
ge (yrs) 66.7  11 63.9  11.1 0.05
Women 29% 17% 0.01
otal cholesterol (mg/dl) 173  37 181  35 NS
DL-C (mg/dl) 42  14 44  18 NS
DL-C (mg/dl) 103  41 107  47 NS
riglycerides (mg/dl) 152  89 169  93 NS
lucose (mg/dl) 105  23 109  27 NS
ean HSCRP (mg/l) 5.9  7.7 6.3  6.9 NS
edian HSCRP (mg/l) 3.4 3.6 NS
eight (lbs) 183  35 189  33 NS
MI (kg/m2) 27.9  4.9 29.2  5.0 NS
Overweight 38% 41% NS
Obese 31% 33% NS
Lipid-lowering meds 65% 60% NS
Statin use 61% 55% NS
MI  body mass index; HDL-C  high-density lipoprotein cholesterol; HSCRP
high sensitivity C-reactive protein; LDL-C  low-density lipoprotein cholesterol;
S  not specified.Table 1 also highlights the baseline differences between the
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HSCRP Reduction Through Exercise Training March 17, 2004:1056–61ontrol and rehabilitation subjects. Of the control subjects, 7
17%) were women (29% on hormone replacement therapy),
hich was significantly lower than the rehabilitation popula-
ion. The control patients were also slightly younger (63.9 
1.1 years vs. 66.7  11.2 years; p  0.05). There were no
ifferences in lipids, use of lipid medications, BMI, or HSCRP
evels between the two groups.
Follow-up assessment (including HSCRP) was obtained on
he day of program completion, which averaged 134 25 days
n rehabilitation patients and 139 27 days in control patients
ollowing the cardiac event (pNS between groups). Table 2
escribes the effects of cardiac rehabilitation and exercise
raining on various parameters of risk. Significant improve-
ents occurred in most parameters of cardiovascular risk
ncluding high-density lipoprotein cholesterol, triglycerides,
xercise capacity (anaerobic threshold and peak oxygen con-
umption [VO2]), and body fat. The percent of subjects
dentified as obese (BMI 30 kg/m2) was reduced from 31%
pon entry to 26% upon completion of the rehabilitation
rogram. This resulted in an increase of patients classified as
verweight (38% to 49%).
Median values of HSCRP decreased 41% (mean reduction
6%) in patients enrolled in cardiac rehabilitation and exercise
raining programs, which contrasts with the lack of change in
SCRP in the control subjects (Tables 2 and 3, Fig. 1). These
able 3. Changes in Lipids, HSCRP, and Body Mass in
ontrol Subjects (n  42)
Baseline Follow-Up p Value
otal cholesterol (mg/dl) 181  35 197  41 NS
DL-C (mg/dl) 44  18 43  19 NS
DL-C (mg/dl) 107  47 118  49 0.07
riglycerides (mg/dl) 169  93 182  102 0.05
lucose (mg/dl) 109  27 109  25 NS
ean HSCRP (mg/l) 6.3  6.9 6.6  7.0 NS
edian HSCRP (mg/l) 3.6 3.7 NS
eight (lbs) 189  33 195  35 NS
MI (kg/m2) 29.2  5.0 29.4 NS
Overweight 41% 43% NS
Obese 33% 36% NS
Table 2. Effects of Cardiac Rehabilitation and
Before
Total cholesterol (mg/dl) 172  38
HDL-C (mg/dl) 41.6  13
LDL-C (mg/dl) 103  41
Triglycerides (mg/dl) 152  89
Glucose (mg/dl) 105  23
Median HSCRP (mg/l) 3.4
Mean HSCRP (mg/l) 5.9  7.7
Anaerobic threshold (ml/kg/min) 11.7  3.0
Peak VO2 (ml/kg/min) 16.6  5.1
Abdominal girth (inches) 39.8  5.0
BMI (kg/m2) 27.9  4.9
Percent fat 28.7  7.8
% Overweight 38%
% Obese 31%
VO2  oxygen consumption; other abbreviations as in Tablbbreviations as in Table 1. (hanges in HSCRP did not correlate with changes in any other
alue studied (change in weight, BMI, percent fat, or exercise
apacity). In addition, control subjects demonstrated an in-
rease in triglycerides over time and trended towards an
ncrease in low-density lipoprotein cholesterol and weight.
levated HSCRP levels (3.0 mg/l) were present in 122
atients (54%) at baseline and 86 patients (38%) upon com-
letion of cardiac rehabilitation and exercise training. In
ontrast, elevated HSCRP levels were present in 57% and 52%
f control subjects at baseline and follow-up respectively. The
istributions of baseline and follow-up HSCRP values are
utlined in Figure 2, demonstrating that values 6 mg/l were
resent in 30% of patients before rehabilitation and were
educed to only 16% following the intervention program.
oreover, values 15 mg/l were present in 9% of patients
efore rehabilitation and were reduced to only 1% following
he intervention program.
The effects of cardiac rehabilitation and exercise training
n HSCRP were then assessed in patients who were actively
aking statin therapy versus those patients who were statin-
aive. Patients on statin therapy (n  143) had a 42%
eduction in HSCRP (3.45 to 2.0 mg/l, p  0.002), which
s similar to that observed in statin-naive patients (n  82)
3.2 to 2.0 mg/l, 38%, p  0.003) (Fig. 3).
We further assessed the non-anthropometric effects of
ardiac rehabilitation and exercise training on median and
igure 1. Median changes in high-sensitivity C-reactive protein (HSCRP)
n cardiac rehabilitation and in control patients with coronary heart disease
cise Training (n  235)
After % Change p Value
174  36 NS
44.4  13.7 7% 0.0001
104  39 NS
141  80 7% 0.05
105  24 NS
2.0 41% 0.002
3.8  5.8 36% 0.0001
11.9  3.7 2% 0.04
18.1  5.9 9% 0.0001
38.9  5.1 2% 0.002
27.8  4.7 NS
27.7  7.2 3% 0.0008
49% 0.01
26% 0.002Exer
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March 17, 2004:1056–61 HSCRP Reduction Through Exercise Trainingean levels of HSCRP by dividing the rehabilitation
atients into those who lost weight, and comparing their
hanges in HSCRP to those patients who gained weight,
uring the three-month intervention program (Table 4 ).
ight patients had no change in weight; 121 patients lost
eight (mean weight change 5.8 lbs, p  0.0001; mean
MI change 0.9 kg/m2, p  0.0001; mean absolute
ercent fat change 1.8%, p  0.001) and also reduced
edian levels of HSCRP by 44% (3.4 to 1.9 mg/l, p 
.003). A total of 106 patients gained weight (mean weight
hange 5.7 lbs, p  0.0001; mean BMI change 0.9
g/m2, p  0.0001; mean absolute percent fat change
0.1%, pNS) and also reduced median levels of HSCRP
y 40% (3.35 to 2.0 mg/l, p  0.004) (Fig. 4).
ISCUSSION
his study demonstrates that therapeutic lifestyle changes,
ffected through a three-month program of cardiac rehabilita-
ion and exercise training, can produce significant improve-
ents in numerous cardiac risk factors, including lipids, exer-
ise capacity, and obesity parameters. To our knowledge, this is
he first report of the favorable effects of this therapy on
SCRP independent of statin therapy and weight reduction.
igure 2. Distribution of high-sensitivity C-reactive protein (HSCRP) in
atients with coronary artery disease (n  235) before and after cardiac
ehabilitation and exercise training.
Table 4. Changes in Weight, BMI, Body Fat,
and Exercise Training in Patients Who Achiev
Weight (B)
A. Weight L
Before
Weight (lbs) 187  37
BMI (kg/m2) 28.6  5.0
Percent fat 30.0  7.9
Median HSCRP (mg/l) 3.4
Mean HSCRP (mg/l) 5.9  7.3
B. Weight G
Before
Weight (lbs) 178  33
BMI (kg/m2) 27.1  4.7
Percent fat 27.2  7.5
Median HSCRP (mg/l) 3.35
Mean HSCRP (mg/l) 5.9  8.1Abbreviations as in Table 1.Atherosclerosis is characterized by inflammation in the
essel wall, particularly at the site of the unstable athero-
clerotic plaque (2). In the active plaque, macrophages and
-lymphocytes produce proinflammatory cytokines such as
nterleukin 6 and 8 and tumor necrosis factor, which
ncrease systemic markers of inflammation such as
-reactive protein (2,14). In addition to being a marker of
nflammation, CRP has recently been found to possess
ctivity that promotes the atherothrombotic process (32–
6). Large cohort studies have shown an association be-
ween elevated levels of circulating CRP and increased risk
or cardiac events or death, in apparently healthy individu-
ls, in patients with stable angina, and in patients following
n ACS (5–12,37–40). We recently reported the high
revalence of metabolic syndrome in our CHD population
nd the markedly elevated levels of HSCRP in this popu-
ation (18).
Our present study found levels of HSCRP to be elevated
n patients following major cardiac events, with the majority
f subjects falling in the fourth and fifth quintiles of
istribution for healthy individuals. As a result of the
ntervention program, we observed a 41% median reduction
n levels of HSCRP. This reduction was of similar or greater
igure 3. Change in high-sensitivity C-reactive protein (HSCRP) follow-
ng cardiac rehabilitation and exercise training in patients taking statins (n
143) and in patients not taking statins (n  82).
HSCRP Following Cardiac Rehabilitation
eight Loss (A) Versus Patients Who Gained
(n  121)
After % Change p Value
181  35 3%  0.0001
27.7  4.6 3%  0.0001
28.2  7.6 6% 0.0001
1.9 44%  0.001
4.1  6.9 31% 0.0065
s (n  106)
After % Change p Value
184  35 3%  0.0001
28.0  4.9 3%  0.0001
27.1  7.5 0 NS
2.0 40%  0.001
3.4  4.0 42% 0.002and
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HSCRP Reduction Through Exercise Training March 17, 2004:1056–61agnitude to that observed in multiple studies using statin
herapy, where median reductions in HSCRP were reported
o be between 15% and 20% (11,20–22). Following publi-
ation of these important observations, statins were discov-
red to possess immunomodulating activity, and at the
resent time generally remain the major treatment option
vailable to the clinician pursuing therapy for elevated
SCRP (41), although recent evidence indicates that other
ipid therapies, including niacin, ezetimibe, and possibly
brates may also reduce HSCRP (42–44).
To assess the unique and independent effects of the non-
harmacologic program, we assessed changes in HSCRP in
atients who were actively taking statin therapy. We found
imilar reductions in HSCRP in patients taking statins and
hose who were not on lipid-lowering agents (Fig. 3), suggest-
ng that the effects of the rehabilitation program are unique and
ncremental over those of statin therapy. This suggests that
otentially a 50% or greater reduction in HSCRP could be
chieved in patients initially treated with statins coupled with
n aggressive nonpharmacologic strategy such as a formal
hase II program of cardiac rehabilitation and exercise training.
There was a positive relationship between adiposity and
SCRP levels across our CHD population, which has been
reviously described, and it is known that adipocytes synthesize
ytokines that are involved in the production of CRP (13–
7,45–47). Previous studies have shown that weight loss can
educe levels of CRP (19). Following nonpharmacologic in-
ervention with cardiac rehabilitation and exercise training, we
bserved significant improvements in abdominal adiposity, as
videnced by reductions in mean abdominal girth and percent
ody fat. To assess whether other aspects of the cardiac
ehabilitation program beyond those of weight reduction could
ave a salutary effect on levels of HSCRP, we divided our
ohort into weight losers and weight gainers (Table 4, Fig. 4).
e observed similar reductions in HSCRP regardless of
ariation in weight, suggesting that other aspects of the
ntervention program, including dietary modification and ex-
rcise training, may have played a prominent role in reducing
nflammation. It is known that n-3 fatty acids, prominent in
he Mediterranean diet promoted in our patients, possess
otent anti-inflammatory effects, including inhibition of TNF
igure 4. Changes in high-sensitivity C-reactive protein (HSCRP) fol-
owing cardiac rehabilitation and exercise training in patients who achieved
eight loss (n  121) versus patients who gained weight (n  106).nd interleukin production (28,48–50). Furthermore, a recentnalysis of 3,638 men participating in the National Health and
utrition Examination Survey III found a strong and inde-
endent inverse relationship between degree of exercise and
evels of CRP (51). Similarly, a small prospective controlled
tudy of exercise training in healthy men reported a significant
all in median CRP levels following nine months of endurance
xercise training (52). These data suggest that multiple com-
onents of the rehabilitation process likely contributed to the
eductions in CRP we observed.
A few study limitations should be mentioned. Our study was
ot randomized, raising the possibility of selection bias, par-
icularly because the control population chose not to attend the
ardiac rehabilitation program. In addition, our control group
as much smaller than the study cohort, and the groups
iffered in a few baseline characteristics (such as age and
ender), but were similar in most parameters assessed. Al-
hough we instructed the intervention group in the Mediter-
anean diet, we did not measure dietary intake or blood levels
f n-3 fatty acids to demonstrate compliance with our recom-
endations.
In summary, despite the study limitations described
arlier, we believe our data demonstrate that formal cardiac
ehabilitation and exercise training produce significant re-
uctions in HSCRP of similar or greater magnitude as
herapy with statin drugs, thus adding to the well-proven
enefits of this therapy. Moreover, the effects of this therapy
ppear to be independent of the effects of statin therapy and
eight loss on HSCRP. In addition to receiving appropriate
harmacotherapy, patients with CHD following cardiac
vents should be routinely referred to cardiac rehabilitation
nd exercise training to provide incremental cardiovascular
enefits in secondary coronary prevention.
eprint requests and correspondence: Dr. Richard V. Milani,
epartment of Cardiology, Ochsner Clinic Foundation, 1514
efferson Highway, New Orleans, Louisiana 70121. E-mail:
milani@ochsner.org.
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